Ligand Pharmaceuticals
LGND
265 hedge funds and large institutions have $2.97B invested in Ligand Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 110 increasing their positions, 90 reducing their positions, and 22 closing their positions.
82% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 22
22% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 90
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
10% more capital invested
Capital invested by funds: $2.71B → $2.97B (+$268M)
6% more funds holding
Funds holding: 251 → 265 (+14)
50% less call options, than puts
Call options by funds: $6.02M | Put options by funds: $12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$34.8M |
| 2 |
MFIMFI
Mesirow Financial Investment Management - Fixed Income
Chicago,
Illinois
|
+$20.9M |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$20M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$18.6M |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$21.8M |
| 2 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$20.3M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$15.7M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$15.5M |
| 5 |
Bank of New York Mellon
New York
|
-$12M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ZIM
276
Zacks Investment Management
Chicago,
Illinois
| – | -$263K | -3,943 | Closed |
|
|
TC
277
TFS Capital
West Chester,
Pennsylvania
| – | -$257K | -3,852 | Closed |
|
|
JG
278
Jefferies Group
New York
| – | -$236K | -3,527 | Closed |
|
279
Los Angeles Capital Management
Los Angeles,
California
| – | -$207K | -3,092 | Closed |
|
|
PP
280
Paloma Partners
Greenwich,
Connecticut
| – | -$206K | -3,073 | Closed |
|
|
EMG
281
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$203K | -3,046 | Closed |
|
282
Group One Trading
Chicago,
Illinois
| – | -$182K | -2,456 | Closed |
|
283
SG Americas Securities
New York
| – | -$140K | -2,092 | Closed |
|
|
IIM
284
Ipswich Investment Management
Beverly,
Massachusetts
| – | -$61K | -802 | Closed |
|
|
PCM
285
Prelude Capital Management
New York
| – | -$49K | -739 | Closed |
|
|
CCMW
286
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
| – | -$28.4K | -425 | Closed |
|
LGND Hedge Fund Activity: Q2 2016 in Review
265 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2016, worth a combined $2.97B — up 9.9% from $2.71B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new LGND positions and 22 closed out — a net gain of 18 holders — while 110 added to existing stakes and 90 trimmed.
The largest buyer was Macquarie Group, adding an estimated $34.8M. The largest seller was AJO LP, cutting an estimated $21.8M.
- 265 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2016, up from 251 in Q1 2016.
- Funds reported $2.97B of Ligand Pharmaceuticals stock for Q2 2016, up 9.9% quarter-over-quarter.
- 40 funds opened new Ligand Pharmaceuticals positions in Q2 2016 and 22 closed out, a net change of +18 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2016 was Macquarie Group, an estimated $34.8M added.
- The largest Ligand Pharmaceuticals seller in Q2 2016 was AJO LP, an estimated $21.8M sold.
Based on aggregated 13F filings for Q2 2016.